https://www.businessline.global/subgroup-analysis-from-phase-3-clinical-trial-supports-efficacy-of-maribavir-over-conventional-therapies-in-transplant-recipients-with-cytomegalovirus-infection-refractory-with-or-without-resistance/press-release/